Drag a card by its title · ⚙ to size, swap or remove

The company

Bionano Genomics, Inc.

BNGO · Nasdaq

Health CareLife-science toolsJust started moving

BNGO stood above a rising 150-day average in 5 of the last 52 weekly readings, including each of the last 5 weeks. It is 0.2% above that average now. Life Science Tools & Research Services: 58% of its 79 stocks in an uptrend (+6 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation: Just started moving
Weeks in an uptrend: 5 in a row
Industry in uptrend: 58% +6 in 4 wk
Insider buys, 12 months: $19K
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 31 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

22 Apr – 21 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2

Sale orders, 12 months0

Buyers · sellers1 · 0

Who	Did	Shares	Traded
Albert LudererInterim Chief Executive	bought	4,000at $1.21	4 Sep 2026filed 9 Sep 2026
Albert LudererInterim Chief Executive	bought	4,000at $1.22	21 Aug 2026filed 21 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders31+4 on the quarter

New · exited9 · 5

Reported value$619K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
CARRET ASSET MANAGEMENT, LLCadded · filed 4 Aug 2026	125,000$141K	+55,000+78.6%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026	89,993$102K	-77,540−46.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	82,388$93K	+14,279+21.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026	51,578$58K	00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026	51,100$58K	+2,400+4.9%
JANE STREET GROUP, LLCnew · filed 14 Aug 2026	35,728$40K	+35,728
PRUDENTIAL FINANCIAL INCadded · filed 12 Aug 2026	31,600$36K	+3,600+12.9%
NORTHERN TRUST CORPadded · filed 13 Aug 2026	24,561$28K	+4,042+19.7%
XTX Topco Ltdnew · filed 14 Aug 2026	16,295$18K	+16,295
Engineers Gate Manager LPadded · filed 14 Aug 2026	11,988$14K	+135+1.1%

31 Dec 2024 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Albert Luderer Interim Chief Executive · last 4 Sep 20262 · 0

Alex Reid Hastie Chief Scientific Officer · last 3 Aug 20260 · 0

Jonathan Dixon V General Counsel · last 3 Aug 20260 · 0

Mark Adamchak Principal Accounting Officer · last 3 Aug 20260 · 0

Mark Oldakowski Chief Operating Officer · last 3 Aug 20261 · 0

Alka Chaubey CHIEF MEDICAL OFFICER · last 3 Jun 20260 · 0

Aleksandar Rajkovic Director · last 14 May 20260 · 0

Christopher J. Twomey Director · last 14 May 20261 · 0

David L. Barker Director · last 14 May 20262 · 0

Kristiina Vuori Director · last 14 May 20260 · 0

Yvonne Linney Director · last 14 May 20260 · 1

R. Erik Holmlin PRESIDENT AND CEO · last 17 Feb 20263 · 0

Same industry

OABI OmniAbLeading+72%

TXG 10x GenomicsLeading+69%

ILMN IlluminaLeading+53%

CRL Charles River Laboratories InternationalLeading+53%

AVTR AvantorLeading+52%

RVTY RevvityLeading+39%

ABSI AbsciLeading+36%

MASS 908 DevicesLeading+35%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202546.3%

Operating profit marginFY 2025 · to 31 Dec 2025-117%

Return on capital employedFY 2025 · to 31 Dec 2025-65.8%

Research spendFY 2025 · to 31 Dec 202539.9%

Share count trendFY 2025 · to 19 Mar 20263.3%

Cash and equivalentsFY 2025 · to 31 Dec 2025$3.0M

Analyst forecasts

No analyst forecasts yet.